Description: PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.
Home Page: phasebio.com
PHAS Technical Analysis
1 Great Valley Parkway
Malvern,
PA
19355
United States
Phone:
610 981 6500
Officers
| Name | Title |
|---|---|
| Mr. Jonathan P. Mow MBA | Pres, CEO & Director |
| Mr. John P. Sharp CPA | Chief Financial Officer |
| Dr. John S. Lee M.D., Ph.D. | Chief Medical Officer |
| Ms. Susan Elizabeth Arnold Ph.D. | Sr. VP of Technical Operations |
| Mr. Kristopher L. Hanson | SVP, Gen. Counsel & Corp. Sec. |
| Mr. Glen G. Burkhardt | Sr. VP of HR |
| Ms. Lauren Richardson | Global Head of Regulatory Affairs & Quality Assurance |
| Mr. Jonathan J. Birchall | Chief Commercial Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 26.18 |
| Price-to-Sales TTM: | 4.2727 |
| IPO Date: | 2018-10-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 60 |